-
公开(公告)号：KR1020010015510A
公开(公告)日：2001-02-26
申请号：KR1020000062334
申请日：2000-10-23
Applicant: 한국과학기술연구원
IPC: A61K31/366
Abstract: PURPOSE: A composition containing tannin, gallic acid or ellagic acid is provided for preventing and treating arteriosclerosis, hyperlipemia and liver diseases. CONSTITUTION: When tannin, gallic acid or ellagic acid are administrated into an animal body, they prevent the deposition of macrophage-lipid complex within the inner surface of arterial duct, decrease the concentration of GOT(glutamate-oxaloacetate transaminase), GPT(glutamate-pyruvate transaminase), gammaGTP(gamma-glutamyl transpeptidase), and lipid in serum, and strongly inhibit the damage of liver cells and the progress of fatty liver. The composition contains an effective of ellagic acid displaying an anticancer activity, that is 0.1 mg to 500 mg/weight kg a day. The composition is preferably administrated into an animal body 5 times a day in a dosage of 1 mg to 100 mg/weight kg.
Abstract translation: 目的：提供含有单宁，没食子酸或鞣花酸的组合物，用于预防和治疗动脉硬化，高脂血症和肝脏疾病。 构成：当将单宁，没食子酸或鞣花酸施用于动物体内时，可防止巨噬细胞 - 脂质复合物在动脉管内表面沉积，降低GOT（谷氨酸 - 草酰乙酸转氨酶）浓度，GPT（谷氨酸 - 丙酮酸转氨酶），γGTP（γ-谷氨酰转肽酶）和血清中的脂质，并且强烈地抑制肝细胞的损伤和脂肪肝的进展。 组合物含有显示抗癌活性的有效的鞣花酸，即每天0.1mg至500mg /重量kg。 组合物优选以1mg至100mg / kg kg的剂量每天施用5次。
-
公开(公告)号：KR1020010015495A
公开(公告)日：2001-02-26
申请号：KR1020000058705
申请日：2000-10-06
Applicant: 한국과학기술연구원
IPC: A23L1/29
Abstract: PURPOSE: A pharmaceutical composition containing one of rutin and Quercetin or the mixture is provided to prevent and treat hyperlipidemia, arteriosclerosis and liver diseases. CONSTITUTION: The rutin is extracted from buckwheat or leaves, stems and flowers of the buckwheat by leaving the materials at a base of pH10-12 by using calcium hydroxide, neutralizing and settling the materials, or by using 20-97% alcohol or water at a high temperature and pressure. The buckwheat and the leaves, stems and flowers also can be dried and pulverized to get powdered buckwheat. The resulting buckwheat flour or buckwheat extract containing 0.01-10wt% of the rutin, quercetin or the mixture of them is added to tomato ketchup, sauce and juice, ramen, noodle, bread, cookies and cracker, soup and gravies, ground beef, or dairy products to get functional foods.
Abstract translation: 目的：提供含有芦丁和槲皮素之一或混合物的药物组合物，用于预防和治疗高脂血症，动脉硬化和肝脏疾病。 构成：通过使用氢氧化钙将材料置于pH10-12的碱性条件下，从荞麦或荞麦的荞麦或叶子，茎和花中提取芦丁，中和和沉淀材料，或通过使用20-97％的酒精或水 高温高压。 荞麦和叶子，茎和花也可以干燥和粉碎以得到荞麦粉。 将含有0.01-10重量％的芦丁，槲皮素或其混合物的荞麦面粉或荞麦提取物加入番茄酱，酱汁和果汁，拉面，面条，面包，饼干和饼干，汤和肉汁，碎牛肉或 乳制品获得功能性食品。
-
公开(公告)号：KR100264392B1
公开(公告)日：2000-08-16
申请号：KR1019980003012
申请日：1998-02-04
Applicant: 한국과학기술연구원
IPC: C12N1/20
Abstract: PURPOSE: A microorganism, Penicillium griseofulvum, producing pyripyropene A and a method for producing cholesterol metabolism inhibitor are provided, wherein pyripyropene A inhibits the activity of cholesterol acyltransferase(ACAT) which adsorbs cholesterol into blood, and is thus used in decreasing the blood cholesterol concentration. CONSTITUTION: Penicillium griseofulvum F1959 separated from soil by Samson method produces pyripyropene A which inhibits the activity of cholesterol acyltransferase(ACAT) and its inhibition concentration IC50 is about 35 ng/ml which is calculated by the equation. The ACAT inhibitor pyripyropene A is produced by the steps of: incubating Penicillium griseofulvum F1959 in a spawn medium containing 0.5% of glucose, 0.2% of yeast extract, 0.5% of polypeptone, 0.1% of potassium phosphate and 0.05% of magnesium sulfate at 29 deg. C for 18 hours; and incubating the microorganism in a growth medium containing 2% of starch, 0.4% of soytone, 0.3% of pama media, 0.1% of potassium phosphate, 0.05% of magnesium sulfate, 0.3% of calcium carbonate and 0.2% of sodium chloride at 29 deg. C for 120 hours.
Abstract translation: 目的：提供微生物青霉菌青霉菌，产生吡柔比星A和生产胆固醇代谢抑制剂的方法，其中吡哆灵A抑制胆固醇酰基转移酶（ACAT）的活性，胆固醇酰基转移酶（ACAT）将胆固醇吸附到血液中，因此用于降低血液胆固醇浓度 。 构成：通过Samson方法从土壤中分离的灰黄霉菌F1959产生抑制胆固醇酰基转移酶（ACAT）活性的白藜芦醇A，其抑制浓度IC50为约35ng / ml，其通过该方程式计算。 通过以下步骤制备ACAT抑制剂pyripyropene A：在含有0.5％葡萄糖，0.2％酵母提取物，0.5％多聚蛋白胨，0.1％磷酸钾和0.05％硫酸镁的产卵培养基中将灰黄青霉F1959温育于29℃ 度。 C 18小时; 并在29℃下将微生物培养在含有2％淀粉，0.4％大豆油，0.3％帕马培养基，0.1％磷酸钾，0.05％硫酸镁，0.3％碳酸钙和0.2％氯化钠的生长培养基中 度。 C 120小时。
-
-
公开(公告)号：KR100184758B1
公开(公告)日：1999-04-01
申请号：KR1019960016412
申请日：1996-05-16
Applicant: 한국과학기술연구원
IPC: C12N15/29
Abstract: 본 발명은 담배로부터 유도 발현되는 메탈로티오네인(metallotionein) 단백질에 관한 것으로, 식물의 병원체 또는 물리적인 상처에 의해서 야생종 담배로부터 발현 유도되는 메탈로티오네인 단백질은 식물체의 병저항성 유도물질 탐색으로 식물체의 병저항성 발현을 확인할 수 있고, 식물체에 가해지는 상처에 대한 방어기작을 조사할 수 있는 표지로서 이용되어 식물체의 스트레스에 대한 저항성 식물의 개발 및 이의 생물학적 치료도 가능하리라 본다.
-
Patent Agency Ranking36.发明公开야생종 담배의 병발생관련단백질-1 및 글루칸 가수분해효소 유전자 및 이를 이용한 식물병 저항성 유도물질의 탐색방법 失效与野生型烟草病害发生有关的蛋白质-1和葡聚糖水解酶基因以及使用它的植物抗病性诱导物的搜索
-
37.发明公开
公开(公告)号：KR1019970006257A
公开(公告)日：1997-02-19
申请号：KR1019950021493
申请日：1995-07-21
Applicant: 한국과학기술연구원
IPC: A61K31/035
Abstract: 본발명은한국인삼으로부터추출한콜레스테릴에스테르전이단백질(cholesteryl ester transfer protein, CETP)의저해제, 이의추출방법및 이를함유하는조성물에관한것으로, 본발명에따라인삼으로부터분리, 정제된폴리아세릴렌계화합물 KRIBB-BP006 및 KRIBB-BF006-1은 CETP를저해하여혈액내콜레스테롤및 저밀도지질단백질의수치를감소시킬수있으므로, 동맥경화증을비롯한각종심혈관질환의예방및 치료제로서이용될수 있다.
Abstract translation: 本发明中，根据本发明的来自人参分离，纯化的聚酰胺基于雪儿化合物涉及一种抑制剂，其从高丽参提取胆固醇酯转移蛋白（胆固醇酯转移蛋白，CETP）和组合物的提取含有它们 KRIBB-BP006和KRIBB-BF006-1可用于抑制CETP它可以降低血液中胆固醇和低密度脂蛋白的水平，作为各种心血管疾病，包括动脉硬化的预防和治疗剂。
-
-
公开(公告)号：KR100362940B1
公开(公告)日：2002-11-30
申请号：KR1020020027396
申请日：2002-05-17
Applicant: 한국과학기술연구원
IPC: A61K31/335
Abstract: 본발명은유효량의헤마테인을함유하는고지혈증및 동맥경화증예방및 치료용조성물에관한것으로, 본발명의조성물은의약용및 식품용조성물을포함한다. 헤마테인은 LDL-항산화제활성을나타내며, 혈중콜레스테롤을현저하게감소시키고, 간마이크로좀 ACAT 활성을강력하게저해하므로, 헤마테인을함유하는본 발명의조성물은고지혈증및 동맥경화증의치료및 예방을위해유용하게사용될수 있다.
Abstract translation: 本发明涉及含有有效量的伴侣H.的高脂血症和动脉硬化的预防和治疗组合物，包括本发明和医疗食物组合物为的组合物。 H.伴侣-在LDL-抗氧化剂是指活性，显著降低血液中的胆固醇，将含有微粒体肝ACAT本发明的组合物中，H.配合，从而强烈地抑制高脂血症和动脉粥样硬化的治疗和预防的活性 可以有用地用于。
-
公开(公告)号：KR100291141B1
公开(公告)日：2001-07-12
申请号：KR1019980037962
申请日：1998-09-15
Applicant: 한국과학기술연구원
IPC: A61K31/70
Abstract: 본 발명은 디오스민(diosmin)을 포함하는 동맥경화증 및 고지혈증의 예방 및 치료용 조성물에 관한 것으로, 디오스민은 동물에게 투여되었을 때 동맥내피에 대식세포-지질 복합체가 침착되는 것을 강력히 억제할 뿐만 아니라, ACAT 및 HMG-CoA 환원효소의 활성을 억제하고, 혈중 콜레스테롤 및 중성지질의 농도를 감소시키므로, 동맥경화증 및 고지혈증의 예방 및 치료제로서 유용하게 사용될 수 있다.
-
-
-
-
-
-
-
-
-
Search Results
78
records
(took 0.025 seconds)
